Pulmonary Drug Delivery Systems Market Trends, Competitive Landscape, Key Developments, Product Type, Application, Region

                                                  Pulmonary Drug Delivery Systems Market

Pulmonary administration is an efficient treatment strategy for lung and other disorders. The Pulmonary Drug Delivery Systems Market can deliver drugs straight to the lungs (PDDS). Maintaining local drug concentration, reducing adverse effects, controlling drug release, promoting drug absorption, extending drug action time, and improving patient compliance are all advantages of PDDS. Polymers have been widely used to create innovative PDDS. Chitosan (CS) is a natural cationic polysaccharide that is abundant in its source. It possesses several unique physicochemical features, as well as strong biocompatibility and biodegradability. For decades, CS has been a prominent biomaterial in pharmaceutics and is widely employed in medication delivery.

Many amino groups can be found in CS. The positive charges present can interact significantly with the negatively charged mucosa membranes, resulting in CS adsorption on the mucosal surface is facilitated, cilia clearance is avoided, and adhesion and penetration rates on the cell membrane are improved. Furthermore, investigations have demonstrated that CS can open cell tight junctions, promoting drug transport through epithelial tissue. As a result, CS is an excellent material for PDDS. This chapter will concentrate on the research advancements and applications of CS in PDDS. Many representative and advanced studies on CS-based PDDS are thoroughly discussed.

The global pulmonary drug delivery systems market is estimated to account for US$ 30,005.80 MN in terms of value in 2020 and is expected to reach US$ 41,072.7 by the end of 2027.

The rising awareness of pulmonary disorders, as well as the availability of numerous pulmonary drug delivery devices, are driving market expansion. The widespread availability of pulmonary drug delivery systems in retail pharmacies and e-pharmacies is likely to boost the industry. Furthermore, increased R&D activities have fostered the development of innovative drug delivery systems, and new product releases by market players are poised to have a substantial impact on global demand for pulmonary drug delivery systems. For example, in October 2018, Philips released the InnoSpire Go, a drinkable mesh nebulizer. It is a portable, hand-held, small-sized, light-weight nebulizer that can dispense medications in a matter of minutes. As a result, the existence of Top manufacturers and their new product offerings are helping to drive market expansion.

During the forecast period, the Pulmonary Drug Delivery Systems Market is expected to grow at a CAGR of 4%. This is due to technological developments, an increase in the incidence of respiratory disorders, and a desire for pulmonary medication delivery as an alternative route of drug delivery. Due to various advantages connected with this delivery system, such as the large surface area present in alveolar sacs, high drug loading efficiency, and high vascularization, pulmonary drug delivery systems are optimal drug approaches when compared to conventional drug delivery approaches. Furthermore, the rising prevalence of chronic respiratory disorders will increase the demand for a pulmonary drug delivery system. The large rise in the targeted patient pool from the previous year will raise demand for pulmonary medication delivery systems. Furthermore, technological advancements in the pulmonary medication delivery system, in conjunction with government and non-government initiatives, will generate attractive prospects for the industry in the coming years.

Segmentations

o     Product Type  Nebulizers MDIs DPIs

o    Application; Asthma  COPD Cystic Fibrosis

o     Region North America  Latin America  Europe  Asia Pacific  Middle East Africa

 Competitive Landscape- 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.

Comments

Post a Comment

Popular posts from this blog

Biobanking Equipment Annual Sales, Size, Major Strategies, Key Companies, Revenue Share Analysis, 2018-2026

Image
                                                                 BioBanking Equipment Biobanking Equipment refers to organized collections of biological samples and related data that are kept for use in future research. Blood, tissue, and urine are common bio specimens handled by bio banks. They are founded either as independent entities or as part of university medical or research institutes, pharmaceutical or biotechnology firms. Blood, enzymes, organ tissue, urine, and DNA, RNA, and cell lines are just a few examples of the samples that can be found in bio banks, which can also be disease- or population-based. As part of precision medicine, the bio banks also assist in the development of a number of novel medicines that are specifically adapted to a patient's unique genetic makeup or tumor's unique genetic profile. Alzheimer's disease, arthritis, cardiovascular illnesses, diabetes, cancer, and psychiatric disorders can all be successfully treated with precision medicine.
Read more

Kidney Cancer Drugs SWOT Analysis by Size and Growth Opportunities by 2022-2030

Image
                                                                                   kidney cancer Drugs A cancer that starts in the kidney's cells is called kidney cancer. A cancer that starts in the kidneys is called kidney cancer. The two bean-shaped organs known as kidneys are each roughly the size of a fist. With one kidney on each side of the spine, they are situated behind the abdominal organs. One of the most prevalent kinds of kidney cancer Drugs in adults is renal cell carcinoma (RCC). Surgery to remove the kidney is done to treat kidney cancer when it has advanced to the point where it is essential to remove the malignant cells. The laparoscopic removal of the tumor-affected area has taken the position of this therapy approach. Tumors are typically treated with medications at advanced stages of the disease. The market for pharmaceuticals to treat Kidney Cancer Drugs is anticipated to reach US$ 5.83 billion in 2022 and grow at a 6.4% CAGR during the next five years (2022
Read more

Medical Carts Market Prospects and Growth Assessment 2030

Image
                                                                         Medical Carts Market A trolley used to transport all the medical supplies needed to operate on or treat patients is referred to as a medical cart. It has cabinets with drawers and trays that are employed in a variety of procedures, including therapeutic, medicinal, and surgical modalities. These carts are frequently used in hospitals, clinics, and other facilities to store medications, supplies, tools, and medical equipment. Medical Carts Market Through simple treatment planning and medication management, these carts help healthcare providers avoid spending vital time and energy on onerous patient data entry and repetitive medication rounds. The global Medical Carts Market is estimated to be valued at US$ 3,479.2 million in 2022 and is expected to exhibit a CAGR of 9.9% during the forecast period (2022-2030) Worldwide demand for Medical Carts Market has significantly increased as a result of the COVID-19. The C
Read more